論文

査読有り 国際誌
2020年8月3日

Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer.

Auris, nasus, larynx
  • Satoshi Koyama
  • ,
  • Kazunori Fujiwara
  • ,
  • Tsuyoshi Morisaki
  • ,
  • Naritomo Miyake
  • ,
  • Takahiro Fukuhara
  • ,
  • Hiromi Takeuchi

記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.anl.2020.07.016

OBJECTIVE: The increase in treatment options resulted in successful treatment with multiple lines of chemotherapy for recurrent and metastatic (RM) head and neck cancer (HNC). The present study aimed to elucidate the beneficial effect of successive treatment for RM-HNC. METHODS: We included 78 patients with RM-HNC who received one or multiple lines of chemotherapy from January 2008 to December 2019. We divided the patients into three groups according to treatment period: January 2008 to November 2012 included those who underwent cancer chemotherapy only with cytotoxic agents (Tox group), December 2012 to March 2017 included those who received cytotoxic agents and cetuximab (Cet group), and March 2017 to December 2019 included those who received cytotoxic agents, cetuximab and immune checkpoint inhibitor nivolumab (Nivo group). Moreover, we compared the overall survival of the three groups. RESULTS: In total, 18, 33, and 27 patients were included in the Tox, Cet, and Nivo groups, respectively. The median overall survival were 8.5 months in the Tox group, 16 months in the Cet group, and 19 months in the Nivo group, and the difference in the result was significant. CONCLUSIONS: Successive treatment with second and subsequent lines of chemotherapy in patients with RM-HNC improves prognosis.

リンク情報
DOI
https://doi.org/10.1016/j.anl.2020.07.016
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32763096
ID情報
  • DOI : 10.1016/j.anl.2020.07.016
  • PubMed ID : 32763096

エクスポート
BibTeX RIS